ABSTRACT

Certolizumab pegol is first pegylated anti-TNF drugs. In this review, safety and efficacy of certolizumab pegol evaluated in patients with psoriatic arthritis. RAPID-PSA is 24 week, double blind, placebo controlled study which assess certolizumab 200 mg/every two weeks and 400 mg/month in patients with psoriatic arthritis. At the end of 24th week, 58.0% and 51.9% of patients achieve ACR 20% response (primary clinical endpoint) for 200 mg/every two weeks and 400 mg/month dosage, respectively. Efficacy of certolizumab start 1 to 2 weeks later. These efficacy continue at least 96 weeks. Additionaly, certolizumab pegol improve functional capacity, fatigue, quality of life, dermatology quality of life index and work productivity. Radiological progression is lower with certolizumab pegol than placebo. Advers events are comperable with other anti-TNF drugs. According to this results, certolizumab pegol is a therapeutic option for DMARD resistant psoriatic arthritis patients.